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Background: Although percutaneous transluminal angioplasty (PTA) has become a common therapeutic standard for
peripheral artery disease (PAD), high restenosis rates in the superficial femoral artery (SFA) remain a major problem.
Nitinol stent implantation is reported to reduce restenosis in SFA after PTA in the general population; however, little is
known about whether the nitinol stent improves primary patency after PTA in hemodialysis patients who are at higher
risk of revascularization failure. The aim of this study was to clarify the effects of nitinol stent implantation for primary
patency in SFA after PTA in hemodialysis patients with PAD.
Methods: Eighty consecutive hemodialysis patients (167 SFA lesions) who underwent PTA with nitinol stents from
January 2006 to January 2008 were compared with 64 hemodialysis patients (128 SFA lesions) who received stainless
steel stents in the preceding 2 years. In the follow-up study to 2 years, incidence of restenosis, amputation, and all-cause
mortality were analyzed. End points between the groups were examined with the Kaplan-Meier and log-rank methods.
Prognostic values for end points were calculated by a Cox univariate analysis and Coxmultivariable regressionmodels. To
statistically minimize the differences in each stent group, a propensity-matched analysis was also performed using the
model including male gender, age, diabetes, hypertension, hyperlipidemia, smoking, incidence of ulcer/gangrene, and
TransAtlantic Inter-Society Consensus (TASC) type CD.
Results: The 2-year primary patency rate was 58% in the nitinol group vs 42% in the stainless steel group (hazard ratio
[HR], 0.58; 95% confidence interval [CI], 0.39-0.84; P .0045), despite a higher prevalence of TASCCD lesion in the
nitinol group (68% vs 49%, P  .0014). In 108 lesions matched after propensity score analysis, the primary patency for
2 years was 64% in the nitinol group vs 42% in the stainless steel group (HR, 0.39; 95% CI, 0.24-0.65; P  .0003). Cox
multivariate models showed nitinol stent (HR, 0.42; 95% CI, 0.25-0.73; P  .002), age (HR, 1.04; 95% CI, 1.01-1.08;
P  .031), and incidence of ulcer/gangrene (HR, 2.35; 95% CI, 1.17-4.75; P  .017) were independent predictors of
restenosis.
Conclusion:These data suggest that nitinol stent implantation improves primary patency in SFA after PTA compared with
the stainless steel stent, even in hemodialysis patients with PAD. (J Vasc Surg 2009;50:1057-62.)Percutaneous transluminal angioplasty (PTA) has been
an accepted selective treatment method for peripheral ar-
tery disease (PAD).1-3 Endovascular stenting might have
beneficial effects on preventing elastic recoil and residual
arterial dissection, resulting in an improved patency after
PTA. Because of in-stent hyperplasia, however, a relatively
higher restenosis rate is a clinical limitation after PTA with
stainless steel stents for lesions of the femoropopliteal (FP)
arteries.4-7 On the other hand, the use of nitinol stents has
been shown to improve primary patency in FP lesions
compared with balloon angioplasty or stainless steel stents,
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doi:10.1016/j.jvs.2009.07.017or both.8-14 Therefore, PTA with nitinol stents has been
commonly performed for FP lesions.
Recently, PTA has also become an effective therapy for
PAD in patients with end-stage renal disease (ESRD) re-
quiring hemodialysis.15 PAD is frequently seen in patients
on hemodialysis. Thus, PTA is one of the most expected
strategies that might improve clinical outcome in hemodi-
alysis patients with PAD. Clinical outcomes after PTA are
not always satisfactory in patients on hemodialysis, how-
ever, because they have vascular calcification and diffuse
lesions. It is unclear in such situations whether nitinol stents
reduce restenosis after PTA for the superficial femoral
arteries (SFA). The aim of the present study was to evaluate
the effects of nitinol stents vs steel stents on preventing
restenosis in hemodialysis patients with SFA lesions.
METHODS
The protocol for this study was approved by the hospi-
tal ethics committee.
Study population. From January 2006, the Smart
nitinol stent (Smart Cordis, Miami, Fla) has been available
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elective PTA with the nitinol stent for peripheral artery
stenosis causing significant obstruction of SFA in 80 con-
secutive hemodialysis patients with 167 lesions from Janu-
ary 2006 to January 2008. They were included as the
nitinol stent group. In the preceding 2 years, 64 consecu-
tive hemodialysis patients with 128 lesions were treated
with the Easy Wallstent stainless steel stents (Boston Scien-
tific, Baltimore,Md) and were included as the stainless steel
stent group. PTA was unsuccessful in four patients, who
were excluded from the study.
Protocol. PTA was performed with standard tech-
niques. All patients received oral aspirin for at least 7 days
before PTA. The procedures were performed through the
ipsilateral femoral artery with an antegrade approach in
patients without lesions near the SFA origin. The approach
in patients with such lesions was from the contralateral
femoral artery. Intra-arterial injection of heparin (5000 IU)
was administered through the sheath after arterial access
was achieved. A stent was implanted in case of an insuffi-
cient PTA result with balloon alone: a residual stenosis with
a luminal diameter 30%, comprising 13 lesions (7.8%) in
the nitinol group and 7 (5.5%) in the stainless steel group,
or a residual flow-limiting dissection after balloon dilata-
tion, comprising 154 (92.2%) in the nitinol group and 121
(94.5%) in the stainless steel group.
Follow-up examinations including Doppler ultrasound
scanning and clinical observations had been conducted 3
months after PTA and every 6 months thereafter up to 2
years at most. In case of suspicion of restenosis after PTA
including by abnormal Doppler waveform, duplex ultra-
sound (DU) arteriography was performed.
The primary end point was incidence of restenosis,
defined as angiographic luminal diameter narrowing50%
in diameter anywhere within the stent or within the 5 mm
borders proximal or distal to the stent, or peak systolic
velocity ratio of 2.4 by DU scans.16 The secondary end
points included amputation due to lower extremity isch-
emia and all-cause mortality. These end points were ob-
tained from hospital records and telephone interviews with
patients by two independent reviewers who were blinded to
PTA procedures. Lesions and critical limb ischemia were
characterized according to TransAtlantic Inter-Society
Consensus (TASC) classification as published.17 In the
present study, we divided lesions into the TASC criteria
AB or CD for the analysis. Amputation was defined as
all amputations, including toe or foot amputation. Diabetes
was diagnosed in patients who had a previous or current
diagnosis of diabetes or who had abnormal results from the
oral glucose tolerance test or hemoglobin A1c levels6.5%.
Statistical analysis. All statistical analyses were per-
formed using SAS 6.10 software (SAS Institute, Cary, NC).
Continuous variables are presented as mean  standard
deviation and were compared using the t test. The end
points between the nitinol stent and stainless steel stent
groups were examined with the Kaplan-Meier method and
compared using the log-rank test. Prognostic values for end
points were calculated by a Cox univariate analysis; further-more, Cox multivariable regression models were used to
determine predictors for the end points. Factors as indi-
cated by P .1 on the univariate Cox analysis were entered
into the multivariable Cox regression models. To statisti-
cally minimize the differences in each stent group to more
fully assess the effect of the stent type, we performed a
propensity-matched analysis. Based on a multivariable lo-
gistic regressionmodel, each patient was assigned a propen-
sity score. Covariates in the model included gender, age,
diabetes, hypertension, hyperlipidemia, smoking, ulcer/
gangrene, TASCCD, and length of stent. The area under
the receiving operating characteristics curve associated be-
tween nitinol stent use and the obtained propensity score
was 0.80. Patients in the nitinol group and those in the
control group werematched 1:1 with two-digit on the basis
of the estimated propensity score. Freedom from restenosis
and clinical events were then analyzed in the propensity-
matched groups. Values of P  .05 were considered statis-
tically significant.
RESULTS
Antegrade access was used in 77 patients (96.3%) in the
nitinol group and in 61 (95.3%) in the stainless steel group.
Contralateral access was used in three patients (3.7%) in the
nitinol group and in three (4.7%) in the stainless steel
group. For all lesions, a final luminal diameter stenosis of
30% without angiographically visual arterial dissection
was seen. No in-hospital complications occurred, including
death, or necessity for additional surgical procedures. No
patients were lost to follow-up.Mean follow-up was 13 6
months in the nitinol stent group and 18 7months in the
stainless steel group.
Table I summarizes the baseline clinical characteristics.
There were significant differences in age, incidence of dia-
betes, and TASC classification. The average age was older
in the stainless steel group, and the nitinol stent group had
higher incidences of diabetes and TASC type CD.
All patients underwent DU imaging, which detected
restenosis in 33 patients (41.3%) in the nitinol group and in
38 patients (59.4%) in the stainless steel group. Of those,
31 patients (38.8%) in the nitinol group and 36 patients
(56.3%) in the stainless steel group underwent angiography
and were found to have restenosis. Fig 1 shows Kaplan-
Meier curves for the primary end point of freedom from
restenosis. The event-free rate from restenosis for 2 years
was 64% in the nitinol group vs 42% in the stainless steel
group (hazard ratio [HR], 0.58; 95% confidence interval
[CI], 0.39-0.84; P  .0045) despite the higher prevalence
of TASC CD lesions in nitinol group (68% vs 49%, P 
.0014). Multivariable analysis to determine effects of the
nitinol stent, even after adjusting for other risk factors at
baseline, showed the beneficial effect of the nitinol stent
remained significant and independent (HR, 0.59; 95% CI,
0.40-0.88; P .011; Table II). However, the nitinol group
required four amputations (5.0%), comprising above knee
in 1, below knee in 1, and toes in 2, and 11 amputations
(17.2%) occurred in the stainless steel group, comprising
above knee in 2, below knee in 3, foot in 1, and toes in 5
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in the nitinol group and 15 (23.4%) in the stainless steel
group died during the follow-up period (HR, 0.53; 95%
CI, 0.21-1.12; P  .076).
Propensity-matched analysis. In 108 lesions matched
after propensity score analysis, baseline characteristics were
well matched (Table III). Variables including age, incidence
of diabetes, smoking status, and TASC classification were also
similar between the two groups.
The event-free rate from restenosis for 2 years was 64%
in the nitinol group compared with 42% in the stainless
steel group (42%), which was significant (HR, 0.39; 95%
CI, 0.24-0.65; P  .0003; Fig 2). On Cox multivariate
models, nitinol stent (HR, 0.42; 95% CI, 0.25-0.73; P 
.002), age (HR, 1.04; 95% CI, 1.01-1.08; P  .031), and
incidence of ulcer/gangrene (HR, 2.35; 95% CI, 1.17-
4.75; P  .017) were independent predictors of restenosis
(Table IV). The event-free rate from target lesion revascu-
larization (TLR) within the first 2 years after stenting was
significantly higher in the nitinol group than in the stainless
steel group (69% vs 49%; HR, 0.40; 95% CI, 0.18-0.89;
P  .024; Table V). However, the event-free rate from
amputation for 2 years was 94% in the nitinol group and
83% in the stainless steel group, which was not statistically
significant (HR, 0.36; 95%, CI 0.08-1.64; P .18). Treat-
ment with the nitinol stent was of borderline significance
for survival from all-cause death (88% in the nitinol group
and 71% in the stainless steel group; HR, 0.35; 95% CI,
Table I. Characteristics of patients
Characteristics
No. (%) or mean  SD
Stent type
PNitinol Stainless steel
Patients, no. 80 64
Male 44 (55) 43 (67) .14
Age, yr 65  11 69  9 .017
Diabetes 65 (81) 40 (63) .012
Hypertension 63 (79) 45 (70) .25
Hyperlipidemia 22 (28) 11 (17) .14
Smoking 13 (16) 19 (30) .053
Coronary artery disease 46 (58) 38 (59) .82
Stroke 6 (8) 10 (16) .13
Indication for PTA .32
Severe claudication 36 (45) 36 (56)
Rest pain 16 (20) 8 (13)
Ulcer/gangrene 28 (35) 20 (31)
Pre-op ABI 0.63  0.30 0.67  0.25 .27
TASC classification (%) .0014
Lesions, no. 167 128
Type AB 54 (32) 65 (51)
Type CD 113 (68) 63 (49)
Stent length, mm 61.4  26.4 55.4  18.8 .014
Medication
Statins 14 (18) 8 (13) .43
Warfarin 6 (8) 9 (14) .20
Ticlopidine 44 (55) 32 (50) .55
Cilostazol 23 (29) 25 (39) .19
Sarpogrelate 19 (24) 13 (20) .62
ABI, Ankle-brachial index; PTA, percutaneous transluminal angioplasty;
SD, standard deviation; TASC, TransAtlantic Inter-Society Consensus.0.10-1.20; P  .093).DISCUSSION
To our knowledge, this is the first report that implan-
tation of nitinol stents for SFA in patients receiving long-
term hemodialysis is associated with significantly improved
primary patency rates compared with stainless steel stents.
Patients who require hemodialysis are at high risk of accel-
erated atherosclerosis.18,19 PAD is a common disease in
patients receiving maintenance hemodialysis, and its prev-
alence in the population is increasing, up to 15% in the
United States.20
Because of the increased rate of amputation and death
after surgical revascularization in patients with renal insuf-
ficiency, especially at high rates for dialysis patients,21 the
less-invasive PTA procedure might be considered the first-
choice therapeutic option for hemodialysis patients. How-
ever, one reason why PTA is not necessarily thought to be
the best strategy of treatment for PAD in hemodialysis
patients is that these patients frequently have complex
lesions.22,23 Our finding was clinically of great significance
because the effects of treatments are not well studied in
hemodialysis patients in whom neointimal growth is pro-
nounced.24,25
In general, treatments for FP lesions are controversial.
Studies have shown that stainless steel stents in FP lesions
do not improve primary patency.4-7 Until now, several
strategies, among them drug-eluting stents and vascular
brachytherapy, have been attempted in FP lesions.8-14,26-28
Reports on these strategies have suggested that nitinol stent
implantation improves primary patency rates in FP/SFA
lesions.8-14
Schillinger et al14 have suggested that implantation of
nitinol stents in the SFA significantly prevents restenosis on
DU imaging compared with a balloon angioplasty group
(37% vs 63%, P  .01).14 Sabeti et al11 reported that
cumulative primary patency rates at 6, 12, and 24 months
were 85%, 75%, and 69% after nitinol stenting, respectively,
vs 78%, 54%, and 34% after stainless steel stenting (P 
Fig 1. Kaplan-Meier curves show cumulative primary patency
after stent implantation..008, log-rank test in propensity score-adjusted analysis).
terval
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thrombogenicity of its surface that results in reducing in-
stent neointimal proliferation.29 The major cause of reste-
nosis after PTA is thought to be neointimal hyperplasia.30
Table II. Predictors for restenosis
Predictor
Univariate
HR (95% CI)
Nitinol stent 0.58 (0.39-0.84)
Male 1.01 (0.99-1.03)
Age 1.06 (1.04-1.07)
Diabetes 2.09 (1.25-3.48)
Hypertension 1.24 (0.82-1.90)
Hyperlipidemia 1.31 (0.86-1.19)
Smoking 1.32 (0.84-2.06)
CAD 1.28 (0.85-1.93)
Stroke 1.87 (0.82-4.28)
Pre-op ABI 0.63 (0.26-1.52)
Ulcer/gangrene 2.49 (1.51-4.11)
Statins 0.58 (0.30-1.19)
Warfarin 0.71 (0.22-2.29)
Ticlopidine 0.74 (0.43-1.28)
Cilostazol 0.54 (0.26-1.15)
Sarpogrelate 0.93 (0.53-1.63)
TASC CD lesions 1.75 (1.21-2.54)
Stent length 1.01 (0.99-1.02)
ABI, Ankle-brachial index; CAD, coronary artery disease; CI, confidence in
Table III. Characteristics of patients after propensity
adjusting
Characteristic
No. (%) or mean  SD Nitinol Stainless steel P
Patients, no. 59 58
Male 35 (59) 40 (69) .28
Age, yr 65  11 67  8 .12
Diabetes 46 (78) 40 (69) .27
Hypertension 43 (73) 40 (69) .64
Hyperlipidemia 15 (25) 12 (21) .54
Smoking 13 (22) 16 (28) .49
CAD 37 (63) 34 (59) .65
Stroke 4 (7) 7 (12) .33
Indication for PTA .37
Severe claudication 28 (48) 34 (59)
Rest pain 12 (20) 7 (12)
Ulcer/gangrene 19 (32) 17 (29)
Pre-op ABI 0.63  0.29 0.67  0.18 .56
Statins 11 (19) 9 (16) .65
Warfarin 4 (7) 7 (12) .33
Medication
Ticlopidine 33 (56) 30 (52) .65
Cilostazol 17 (29) 23 (40) .22
Sarpogrelate 12 (20) 12 (21) .96
TASC classification .26
Lesions, no. 108 108
Type AB 38 (35) 46 (43)
Type CD 70 (65) 62 (57)
Stent length, mm 60.3  22.1 56.6  16.8 .19
ABI, Ankle-brachial index; CAD, coronary artery disease; PTA, percutane-
ous transluminal angioplasty; SD, standard deviation; TASC, TransAtlantic
Inter-Society Consensus.Plasma coagulation factors are also activated in hemodialy-sis patients.31 These actions might be related to mural
thrombus formation, leading to an early stage of restenosis
after PTA. A nitinol stent, therefore, is one of the most
logical devices for PTA.
Although we found efficacies of nitinol stent implanta-
tion for SFA lesions in hemodialysis patients compared with
stainless steel stents, the primary patency for 2 years was
65% in the nitinol group. Lugmayr et al32 reported that the
primary 2-year patency rate was 85% after treatment of
complex lesions in the SFA and popliteal artery in nondi-
alysis patients. Thus, the restenosis rate was quite higher in
hemodialysis patients, showing the difficulty of treatment
for PAD in hemodialysis patients. In such situations, much
intensive care, including medical treatment after PTA,
might be effective. A recent report has suggested that
Fig 2. Kaplan-Meier curves show cumulative primary patency
after stent implantation in propensity-adjusted groups.
Multivariate
P HR (95% CI) P
.0045 0.59 (0.40-0.88) .011
.25
.0032 1.04 (1.01-1.07) .019
.0046 2.86 (1.15-5.64) .023
.30
.22
.23
.24
.14
.31
.0004 2.20 (1.37-3.51) .0010
.19
.57
.29
.11
.80
.0032 1.62 (0.89-2.96) .11
.28
; HR, hazard ratio; TASC, TransAtlantic Inter-Society Consensus.cilostazol treatment not only prevents restenosis but also
, Tra
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tients with PAD.33 Additional pharmacologic strategies
like this might have beneficial effects on clinical outcome.
We could not demonstrate a statistically significant
difference in rates of amputation and death in the study,
although there were tendencies toward higher reduction
rates of those adverse outcomes in patients treated with
nitinol stents. This might be due to a relatively small sample
size, and further investigations are needed to clarify the
results.
The present study has some limitations. First, it was
retrospective, and the assignment to nitinol or stainless
steel stents was not randomized. Although we used pro-
pensity score-adjusted analysis, much chance for bias ex-
isted. There might be a time-related lag bias and treatment
selection bias. In other words, no nitinol stents were used in
the first 2 years, and no steel stents were used in the second
2 years. Second, this was a single-center study with a small
sample size, as described. Third, we used the Smart stent as
the only nitinol stent in the present study and have no data
on other nitinol stents. Fourth, we could not perform
follow-up angiography in all patients, so some patients
Table IV. Predictors for restenosis after propensity adjust
Predictor
Univariate
HR (95% CI)
Nitinol stent 0.39 (0.24-0.65)
Male 1.06 (0.65-1.73)
Age 1.04 (1.02-1.07)
Diabetes 2.11 (1.08-4.13)
Hypertension 1.17 (0.44-3.12)
Hyperlipidemia 1.13 (0.68-1.86)
Smoking 1.38 (0.83-2.32)
Coronary artery disease 1.06 (0.63-1.81)
Stroke 1.08 (0.47-2.53)
Pre-op ABI 0.49 (0.18-1.35)
Ulcer/gangrene 2.20 (1.39-3.48)
Statins 0.72 (0.43-1.21)
Warfarin 0.87 (0.32-2.39)
Ticlopidine 0.66 (0.41-1.09)
Cilostazol 0.57 (0.28-1.15)
Sarpogrelate 0.93 (0.53-1.62)
TASC CD lesions 2.01 (0.97-4.13)
Stent length 1.01 (0.99-1.02)
ABI, Ankle-brachial index; CI, confidence interval; HR, hazard ratio; TASC
Table V. Event-free survival at 2 years after propensity
score matching
Event Nitinol
Stainless
steel HR (95% CI) P
TLR, % 69 49 0.40 (0.18-0.89) .024
Amputation, % 94 83 0.36 (0.08-1.64) .18
All-cause death, % 88 71 0.35 (0.10-1.20) .093
CI, Confidence interval;HR, hazard ratio; TLR, target lesion revasculariza-
tion.might have had a normal Doppler waveform or no ischemicsymptoms because of adequate collateral flow even if reste-
nosis at the stent site existed.
CONCLUSIONS
Nitinol stent implantation for SFA lesions is a useful
strategy in hemodialysis patients who are at high risk of
atherosclerosis and results in improving primary patency
and reducing a TLR rate. A large-scale randomized multi-
center study is needed to confirm the results of this study.
AUTHOR CONTRIBUTIONS
Conception and design: YK, HI
Analysis and interpretation: TA, HT
Data collection: MT, YK, TT
Writing the article: YK, HI, YK
Critical revision of the article: YK, HT, TA, TM
Final approval of the article: TM
Statistical analysis: HT
Obtained funding: Not applicable
Overall responsibility: TM
REFERENCES
1. Anderson PL, Gelijns A, Moskowitz A, Arons R, Gupta L, Weinberg A,
et al. Understanding trends in inpatient surgical volume: vascular inter-
ventions, 1980-2000. J Vasc Surg 2004;39:1200-8.
2. Kudo T, Chandra FA, Ahn SS. The effectiveness of percutaneous
transluminal angioplasty for the treatment of critical limb ischemia: a 10
year experience. J Vasc Surg 2005;41:423-35.
3. Faglia E, Dalla Paola L, Clerici G, Clerissi J, Graziani L, FusaroM, et al.
Peripheral angioplasty as the first-choice revascularization procedure in
diabetic patients with critical limb ischemia: prospective study of 993
consecutive patients hospitalized and followed between 1999 and 2003.
Eur J Vasc Endovasc Surg 2005;29:620-7.
4. Gray BH, Sullivan TM, ChildsMB, Young JR, Olin JW.High incidence
of restenosis/reocclusion of stents in the percutaneous treatment of
long-segment superficial femoral artery disease after suboptimal angio-
Multivariate
P HR (95% CI) P
.0003 0.42 (0.25-0.73) .0020
.80 . . . . . .
.0002 1.04 (1.01-1.08) .031
.027 2.43 (0.90-5.57) .078
.74 . . . . . .
.63 . . . . . .
.22 . . . . . .
.81 . . . . . .
.85 . . . . . .
.17 . . . . . .
.0008 2.35 (1.17-4.75) .017
.22 . . . . . .
.78 . . . . . .
.15 . . . . . .
.12 . . . . . .
.80 . . . . . .
.058 1.38 (0.62-3.11) .42
.13 . . . . . .
nsAtlantic Inter-Society Consensus.mentplasty. J Vasc Surg 1997;25:74-83.
JOURNAL OF VASCULAR SURGERY
November 20091062 Kawamura et al5. Vroegindeweij D, Vos LD, Tielbeek AV, Buth J, vd Bosch HC. Balloon
angioplasty combined with primary stenting versus balloon angioplasty
alone in femoropopliteal obstructions: a comparative randomized
study. Cardiovasc Intervent Radiol 1997;20:420-5.
6. Zdanowski Z, Albrechtsson U, Lundin A, Jonung T, Ribbe E, Thörne
J, et al. Percutaneous transluminal angioplasty with or without stenting
for femoropopliteal occlusions? A randomized controlled study. Int
Angiol 1999;18:251-5.
7. Cejna M, Thurnher S, Illiasch H, Horvath W, Waldenberger P, Hornik
K, et al. PTA versus Palmaz stent placement in femoropopliteal artery
obstructions: a multicenter prospective randomized study. J Vasc Interv
Radiol 2001;12:23-31.
8. Lugmayr HF, Holzer H, Kastner M, Riedelsberger H, Auterith A.
Treatment of complex atherosclerotic lesions with nitinol stents in the
superficial femoral and popliteal arteries: a midterm follow-up. Radiol-
ogy 2002;222:37-43.
9. Jahnke T, Voshage G, Muller-Hulsbeck S, Grimm J, Heller M, Bross-
mann J. Endovascular placement of self-expanding nitinol coil stents for
the treatment of femoropopliteal obstructive disease. J Vasc Interv
Radiol 2002;13:257-66.
10. Mewissen MW. Self-expanding nitinol stents in the femoropopliteal
segment: technique and mid-term results. Tech Vasc Interv Radiol
2004;7:2-5.
11. Sabeti S, Schillinger M, Amighi J, Sherif C, Mlekusch W, Ahmadi R, et
al. Primary patency of femoropopliteal arteries treated with nitinol
versus stainless steel self-expanding stents: propensity score-adjusted
analysis. Radiology 2004;232:516-21.
12. Vogel TR, Shindelman LE, Nackman GB, Graham AM. Efficacious use
of nitinol stents in the femoral and popliteal arteries. J Vasc Surg
2003;38:1178-84.
13. Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, et
al. Sustained benefit at 2 years of primary femoropopliteal stenting
compared with balloon angioplasty with optional stenting. Circulation
2007;115:2745-9.
14. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, et al.
Balloon angioplasty versus implantation of nitinol stents in the superfi-
cial femoral artery. N Engl J Med 2006;354:1879-88.
15. Graziani L, Silvestro A, Bertone V, Manara E, Alicandri A, Parrinello G,
et al. Percutaneous transluminal angioplasty is feasible and effective in
patients on chronic dialysis with severe peripheral artery disease. Neph-
rol Dial Transplant 2007;22:1144-9.
16. Ranke C, Creutzig A, Alexander K. Duplex scanning of the peripheral
arteries: correlation of the peak velocity ratio with angiographic diam-
eter reduction. Ultrasound Med Biol 1992;18:433-40.
17. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes
FG; TASC II Working Group: Inter-Society Consensus for the Man-
agement of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007;
45:S5-67.
18. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated athero-
sclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;
290:697-701.19. Goldsmith DJA, Covic A. Coronary artery disease in uremia: etiology,
diagnosis, and therapy. Kidney Int 2001;60:2059-78.
20. United States Renal Data System. Annual data report. Bethesda, MD:
National Institute of Health, National Institute of Diabetes and Diges-
tive and KidneyDisease, Division of Kidney, Urologic andHematologic
Disease 2000;26:339-48.
21. O’Hare AM, Sidawy AN, Feinglass J, Merine KM, Daley J, Khuri S,
et al. Influence of renal insufficiency on limb loss and mortality after
initial lower extremity surgical revascularization. J Vasc Surg 2004;
39:709-16.
22. Leskinen Y, Salenius JP, Lehtimäki T, Huhtala H, Saha H. The preva-
lence of peripheral arterial disease and medial arterial calcification in
patients with chronic renal failure: requirements for diagnostics. Am J
Kidney Dis 2002;40:472-9.
23. O’Hare AM. Management of peripheral arterial disease in chronic
kidney disease. Cardiol Clin 2005;23:225-36.
24. Nakazawa G, Tanabe K, Aoki J, YamamotoH,Higashikuni Y, Onuma Y,
et al. Impact of renal insufficiency on clinical and angiographic outcomes
following percutaneous coronary intervention with sirolimus-eluting
stents. Catheter Cardiovasc Interv 2007;69:808-14.
25. Aoyama T, Ishii H, Toriyama T, Takahashi H, Kasuga H, Murakami R,
et al. Sirolimus-eluting stents versus bare metal stents for coronary
intervention in Japanese patients with renal failure on hemodialysis. Circ
J 2008;72:56-60.
26. Minar E, Pokrajac B, Ahmadi R, Maca T, Seitz W, Stümpflen A, et al.
Brachytherapy for prophylaxis of restenosis after long-segment femoro-
popliteal angioplasty: pilot study. Radiology 1998;208:173-9.
27. Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A,
et al. Sirolimus-eluting stents for the treatment of obstructive super-
ficial femoral artery disease: six-month results. Circulation 2002;
106:1505-9.
28. Adam DJ, Bradbury AW. TASC II document on the management of
peripheral arterial disease. Eur J Vasc Endovasc Surg 2007;33:1-2.
29. Thierry B, Merhi Y, Bilodeau L, Trepanier C, Tabrizian M. Nitinol
versus stainless steel stents: acute thrombogenicity study in an ex vivo
porcine model. Biomaterials 2002;23:2997-3005.
30. Gray BH, Sullivan TM, ChildsMB, Young JR, Olin JW.High incidence
of restenosis/reocclusion of stents in the percutaneous treatment of
long-segment superficial femoral artery disease after suboptimal angio-
plasty. J Vasc Surg 1997;25:74-83.
31. Notohamiprodjo M, Andrassy K, Bommer J, Ritz E. Dialysis mem-
branes and coagulation system. Blood Purif 1986;4:130-41.
32. Lugmayr HF, Holzer H, Kastner M, Riedelsberger H, Auterith A.
Treatment of complex atherosclerotic lesions with nitinol stents in the
superficial femoral and popliteal arteries: a midterm follow-up. Radiol-
ogy 2002;222:37-43.
33. Ishii H, Kumada Y, Toriyama T, Aoyama T, Takahashi H, Yamada S, et
al. Cilostazol improves long-term patency after percutaneous translu-
minal angioplasty in hemodialysis patients with peripheral artery disease.
Clin J Am Soc Nephrol 2008;3:1034-1040.Submitted Apr 18, 2009; accepted Jul 3, 2009.
